More than 170 countries have authorized use of AstraZeneca’s shot, but it hasn’t been authorized for use in the U.S.
The drugmaker originally planned to seek an emergency use authorization from the FDA for the shot in mid-April, but decided to seek full approval instead, according to The Hill. Full approval requires at least six months of data.
“It’s a good vaccine, and we just want to make sure it’s ready to be used if needed,” AstraZeneca’s CEO Pascal Soriot said, The Hill reported.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
